Murphy Pohlad Asset Management LLC Bristol Myers Squibb CO Transaction History

Murphy Pohlad Asset Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	SELL	$57.89 - $64.73 $15,340 - $17,153	-265 Reduced 6.97%	3,538 $205,000
Q4 2022 Feb 06, 2023	BUY	$68.48 - $81.09 $37,664 - $44,599	550 Added 16.91%	3,803 $273,000
Q3 2022 Oct 24, 2022	SELL	$0.13 - $76.84 $24 - $14,599	-190 Reduced 5.52%	3,253 $231,000
Q1 2022 May 05, 2022	SELL	$61.48 - $73.72 $15,062 - $18,061	-245 Reduced 6.64%	3,443 $251,000
Q4 2021 Feb 11, 2022	SELL	$53.63 - $62.52 $26,815 - $31,260	-500 Reduced 11.94%	3,688 $229,000
Q3 2021 Nov 09, 2021	SELL	$59.17 - $69.31 $580,457 - $679,931	-9,810 Reduced 70.08%	4,188 $247,000
Q2 2021 Aug 11, 2021	SELL	$61.91 - $67.42 $209,255 - $227,879	-3,380 Reduced 19.45%	13,998 $935,000
Q1 2021 Apr 20, 2021	BUY	$59.34 - $66.74 $5,637 - $6,340	95 Added 0.55%	17,378 $1.1 Million
Q4 2020 Feb 05, 2021	SELL	$57.74 - $65.43 $254,922 - $288,873	-4,415 Reduced 20.35%	17,283 $1.07 Million
Q3 2020 Nov 09, 2020	BUY	$57.43 - $63.64 $582,914 - $645,946	10,150 Added 87.89%	21,698 $1.31 Million
Q1 2020 May 13, 2020	SELL	$46.4 - $67.43 $96,744 - $140,591	-2,085 Reduced 15.29%	11,548 $643,000
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $19,684 - $25,676	400 Added 3.02%	13,633 $875,000
Q1 2019 May 07, 2019	SELL	$45.12 - $53.8 $145,060 - $172,967	-3,215 Reduced 19.55%	13,233 $631,000
Q3 2018 Nov 09, 2018	BUY	$55.19 - $62.25 $12,417 - $14,006	225 Added 1.39%	16,448 $1.02 Million
Q3 2017 Oct 26, 2017	BUY	$55.23 - $63.74 $895,996 - $1.03 Million	16,223	16,223 $1.03 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Murphy Pohlad Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Murphy Pohlad Asset Management LLC with notifications on news.